Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.

NCT01643603 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT01643603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01643603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2012
Completion date
October 9, 2018
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin's lymphoma, lymphoid leukemia, multiple myeloma, myelodysplastic syndrome, myeloid leukemia, non-hodgkin's lymphoma